The CDC reported over 80,000 opioid overdose deaths in the United States in a single recent year, and research consistently shows that the type of treatment someone receives matters as much as whether they receive it at all. Choosing opioid addiction treatment is one of the most consequential decisions a person or family will make, and knowing what separates effective care from ineffective care is where that decision has to start.
Why treatment choice determines outcomes
According to SAMHSA’s 2023 National Survey on Drug Use and Health, fewer than 25% of people with opioid use disorder receive any form of specialty treatment in a given year. Of those who do enter treatment, outcomes vary enormously depending on the components of the program. Not all treatment is equal. Programs that combine medical supervision, evidence-based medication, and structured behavioral therapy produce measurably better results than programs that rely on willpower, abstinence-only protocols, or peer support alone.
The research on this is not ambiguous. The setting, the clinical components, and the quality of the discharge plan all directly affect whether recovery holds past the first year. Understanding what distinguishes effective opioid addiction treatment from ineffective treatment is not just useful background knowledge. It is the framework for making a decision that keeps someone alive.
The core components every effective program must have
NIDA’s principles of effective treatment, updated in 2023, identify several non-negotiable elements for opioid use disorder care: medically supervised detoxification, access to FDA-approved medications, behavioral therapy, and a structured aftercare plan. A program missing any one of these is not a complete program, and the absence of any component increases relapse risk significantly.
Medical detox addresses the immediate physical withdrawal from opioids, which without supervision can involve severe complications. Medication-assisted treatment (MAT) stabilizes the brain’s opioid receptors and reduces cravings during and after detox. Behavioral therapy builds the cognitive and emotional skills needed to maintain sobriety when stress, triggers, or cravings arise. And discharge planning ensures that the work done in residential treatment connects to ongoing support rather than ending abruptly on the day of departure.
Medication-assisted treatment (MAT)
A 2023 New England Journal of Medicine analysis of more than 17,000 patients with opioid use disorder found that those treated with buprenorphine or methadone had a 50% lower risk of overdose death compared to those who received no medication. That is not a modest improvement. It is the difference between life and relapse-and-death for a significant portion of patients.
MAT works by binding to the same opioid receptors in the brain that heroin, fentanyl, and prescription opioids activate, but without producing the euphoric high that drives continued use. Buprenorphine (often prescribed as Suboxone) and methadone reduce withdrawal symptoms and cravings. Naltrexone blocks opioid receptors entirely and is used after detox is complete. What this means in practice: when you evaluate any residential program, ask directly whether they offer MAT and which FDA-approved medications are available. A facility that refuses MAT on philosophical or religious grounds is not following clinical evidence. That is a red flag, not a program philosophy worth respecting.
Behavioral therapy that runs alongside MAT
A 2022 SAMHSA report reviewing outcomes across 1,200 opioid treatment programs found that patients who received both MAT and structured behavioral therapy had significantly higher rates of treatment retention and lower rates of illicit opioid use at 12 months compared to those who received medication alone. The mechanism is straightforward: medication stabilizes the brain, and therapy rewires the habits, thought patterns, and emotional responses that drove use in the first place.
Cognitive Behavioral Therapy and contingency management are the most thoroughly researched modalities for opioid use disorder. CBT helps identify and interrupt the thinking patterns that lead to use. Contingency management reinforces abstinence through structured positive rewards. When you speak to a facility, ask specifically what therapy modalities they use, how many individual therapy sessions occur per week, and whether therapy is provided by licensed counselors or simply facilitated by peers.
How to evaluate a facility before you commit
The Joint Commission, which accredits behavioral health programs across the United States, published data in 2023 showing that accredited addiction treatment programs report significantly lower rates of adverse events and higher rates of patient satisfaction than non-accredited facilities. Accreditation and state licensure are not bureaucratic checkboxes. They are the floor of accountability.
When evaluating any program, verify four things: New Hampshire state licensure through the Bureau of Drug and Alcohol Services, accreditation through CARF or The Joint Commission, staff credentials that include board-certified addiction medicine physicians and licensed clinical counselors, and a staff-to-patient ratio that allows for meaningful individual attention. A program that cannot readily provide documentation for any of these deserves closer scrutiny before you commit. If you’re also considering how facilities approach other substance programs, the same evaluation criteria apply whether you’re looking at opioid-specific care in northern New Hampshire or treatment for a different primary substance.
Residential vs. outpatient: matching level of care to severity
The American Society of Addiction Medicine (ASAM) criteria, the clinical standard for matching patients to appropriate levels of care, identify several factors that indicate residential treatment over outpatient: an unstable home environment, prior failed attempts at outpatient care, a need for medically supervised detox, or co-occurring mental health conditions that require intensive monitoring.
Outpatient treatment works well for lower-severity opioid use disorder when the person has strong social support, stable housing, and no history of failed outpatient attempts. Residential care is the right call when those conditions are not met. Before you start calling facilities, honestly assess which scenario applies. Choosing outpatient treatment for someone who needs residential care does not save money; it increases the risk of relapse, readmission, and overdose.
Questions to ask any treatment program
SAMHSA’s 2023 treatment guidance specifically notes that patients and families who ask targeted questions before admission report better treatment matches and fewer unexpected disruptions to care. Here are the five questions to ask every program before signing anything.
Do you offer MAT with buprenorphine or methadone, and will it continue after detox? What is the typical length of the residential program, and what determines when a patient transitions out? What does the discharge plan include, and who coordinates ongoing care after I leave? How is family involved during treatment, and what communication can family members expect? Which insurance plans do you accept, and does your team verify benefits before admission?
These are direct questions. Any program that deflects, gives vague answers, or pressures you to decide before answering them is not operating in your interest.
Understanding insurance coverage for opioid treatment
The Mental Health Parity and Addiction Equity Act requires that commercial insurance plans cover substance use disorder treatment at the same level as medical and surgical care. A 2022 report from the U.S. Department of Labor found that despite this federal requirement, insurers routinely impose more restrictive prior authorization and benefit limitations on addiction treatment than on comparable medical care.
In practical terms, this means your coverage exists on paper, but the actual benefits require verification. Commercial plans including Aetna, Anthem, Cigna, Harvard Pilgrim, and Tufts, as well as Tricare and New Hampshire Medicaid options like WellSense, AmeriHealth Caritas, and Granite State Health Plan, are all required to cover residential detox and MAT. The concrete step: call the member services number on the back of the insurance card and ask specifically about coverage for residential detox, MAT medications, and any prior authorization requirements before you choose a facility.
Red flags that signal a program is not the right fit
The Federal Trade Commission has issued repeated warnings about predatory practices in addiction treatment, including programs that use high-pressure sales tactics, obscure their accreditation status, or accept patients far outside their appropriate level of care. These are not minor concerns. They are signals to walk away before any money changes hands or paperwork is signed.
Specific red flags include: a program that prohibits or discourages MAT, a facility that cannot produce its state license and accreditation documentation on request, discharge plans that consist of nothing more than a referral list, staff who pressure you to make a same-day decision, and no clear policy on family communication during treatment. Run this list against every facility you speak to. A program that is genuinely good at treating opioid use disorder will have straightforward answers to all of these. If you’re also evaluating care for someone managing opioid and benzodiazepine dependence together, understanding the differences in safer benzodiazepine detox options helps clarify why combined medical supervision matters.
What aftercare determines about long-term recovery
A 2023 study published in JAMA Psychiatry tracking 3,400 patients over 24 months found that patients who participated in structured continuing care after residential treatment had a 40% lower rate of relapse at 12 months compared to those who received no continuing care. Residential treatment stabilizes someone medically and behaviorally. Continuing care is what determines whether that stability holds.
Strong aftercare includes a step-down to outpatient treatment, connection to a prescriber for ongoing MAT, peer recovery support services, and resources addressing housing stability. These are not optional add-ons. They are the mechanisms that bridge residential treatment to sustained recovery. Before choosing a residential program, ask to see a sample discharge plan. What happens on day one after leaving tells you exactly how seriously a program takes long-term outcomes. For those navigating recovery alongside other substance use histories, programs that address heroin use in New Hampshire often share the same aftercare infrastructure and can be evaluated using the same framework.
What to do this week
Identify one or two residential programs that offer medically supervised detox and MAT. Confirm they hold current New Hampshire state licensure and CARF or Joint Commission accreditation. Then call member services on the insurance card to verify residential detox and MAT coverage before the first facility visit. This is a same-week task, not a someday task. The information needed to make a sound decision is available with three phone calls, and making those calls now is the move that protects against a costly mismatch later.
Frequently asked questions
What is the most effective medication used in opioid addiction treatment?
Buprenorphine and methadone have the strongest evidence base. Both reduce cravings and withdrawal symptoms without producing a high, and both are associated with significantly lower overdose mortality rates. Naltrexone is an alternative for patients who have already completed detox and have no physical dependence remaining. The right medication depends on individual medical history, which is a decision made with a board-certified addiction medicine physician, not a facility intake coordinator.
How long does opioid addiction treatment take?
Medically supervised detox typically runs five to ten days depending on the opioids involved and the severity of dependence. Residential treatment following detox commonly runs 28 to 90 days. NIDA research indicates that treatment lasting fewer than 90 days produces significantly worse outcomes for opioid use disorder compared to longer stays. Aftercare, including outpatient therapy and MAT, often continues for a year or more.
Does new hampshire medicaid cover opioid rehab?
Yes. WellSense, AmeriHealth Caritas, and Granite State Health Plan are all required under federal parity law to cover substance use disorder treatment, including residential detox and MAT. Coverage details, including prior authorization requirements and in-network facility requirements, vary by plan. Call member services on the insurance card to get specific benefit information before choosing a facility.
Is MAT just trading one addiction for another?
No. This is one of the most persistent misconceptions in opioid treatment. FDA-approved medications like buprenorphine and methadone are prescribed at doses calibrated to prevent withdrawal and reduce cravings, not to produce intoxication. Patients on MAT are stable, functional, and far less likely to die of overdose. NIDA describes withholding MAT from patients who need it as clinically indefensible, and the research on mortality reduction is consistent across decades of study.
What should a discharge plan from opioid rehab include?
A strong discharge plan names a specific outpatient provider, confirms a prescription or appointment for ongoing MAT, connects the patient to peer recovery support services, addresses housing stability if relevant, and schedules a follow-up appointment within the first week after discharge. A discharge plan that is simply a list of phone numbers is not adequate. Ask to see a sample plan before choosing any residential program.
